Xi’s squeeze taking the verve out of China Inc

Posted By : Rina Latuperissa
13 Min Read

[ad_1]

China’s Sinovac vaccine is quickly changing from a hoped-for diplomatic triumph to a sign that China isn’t yet ready for the global cutting-edge prime time.

Initially hailed as the developing world’s trump card against Covid-19, the vaccine is suddenly facing an epidemiological crisis. Efficacy doubts have Singapore deciding people who received Sinovac should be characterized as unvaccinated. In Thailand, health officials claim more than 600 Sinovac-jabbed medical workers have tested positive for coronavirus.

It’s an embarrassing turn for Xi’s “vaccine diplomacy” scheme – one that initially caught the US flatfooted. And it’s bigger than that. The Sinovac stumble symbolizes both China’s growing number of policy mishaps as well as its broad tendency to put the quantity of growth ahead of its quality.

Count Cathie Wood of Ark Investment Management is among those growing skeptical of Xi’s economic management. In her case, it’s Chinese President Xi Jinping’s fast-widening tech crackdown that raises big questions about the new model he appears to be developing on the fly.

Wood, one of Wall Street’s biggest names of the moment, has been selling mainland tech stocks following Xi’s moves against fintech giant Ant Group, ride-sharing behemoth Didi Global and a fast-growing number of tech disrupters. The China weighting of her flagship Ark Innovation ETF fund plunged to less than 1% – way down from 8% in February.

[ad_2]

Source link

Share This Article
Leave a comment